GlassScriptPhysician profile
William Jason Mcmanus
NPI 1265517619
$8,175.37
in general payments reported to CMS, 2019-2025
42 companies · $478 in 2025
The $478 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $627 · 2021: $1,132 · 2022: $1,067 · 2023: $2,494 · 2024: $984 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,030 · Travel and Lodging: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.34 |
| Travel and Lodging | $925.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $993.77 | 2023 | Carto 3 |
| Janssen Pharmaceuticals, INC | $936.54 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $935.92 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $704.06 | 2019-2025 | |
| Pfizer INC. | $626.96 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $366.25 | 2019-2023 | |
| Boston Scientific Corporation | $366.23 | 2022-2024 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Abbott Laboratories | $360.04 | 2019-2024 | Amplatzer Amulet |
| Astrazeneca Pharmaceuticals LP | $294.52 | 2019-2025 | Farxiga |
| Amgen INC. | $276.23 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $267.39 | 2022-2025 | Verquvo, Winrevair |
| Biosense Webster, INC. | $251.37 | 2021-2024 | Nuvision Ice Catheter, Carto 3, Na |
| Amarin Pharma, INC. | $212.40 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.47 | 2021-2025 | |
| United Therapeutics Corporation | $165.68 | 2024-2025 | Tyvaso, Tyvaso |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcmanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.